Groundbreaking Clinical Trial Slashes LDL Cholesterol by 62%.
Scientists have developed a one-time gene-editing therapeutic targeting the PCSK9 gene to permanently reduce low-density lipoprotein (LDL) cholesterol. Recent clinical data confirms a 62% reduction in serum LDL levels. This ... Read More